Arizona Tribune - Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

NYSE - LSE

RBGPF	-1.15%	68.56	$
RYCEF	1.97%	20.83	$
RIO	2.97%	105.3	$
CMSC	-0.31%	21.215	$
JRI	-0.16%	12.39	$
VOD	-0.47%	15.935	$
RELX	1.45%	35.9	$
NGG	-0.72%	80.04	$
BCC	0.61%	82.27	$
BCE	-0.17%	23.74	$
GSK	0.87%	52.415	$
CMSD	-0.48%	21.02	$
BP	-0.61%	44.865	$
AZN	0.93%	166.029	$
BTI	-0.92%	56.185	$

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

TECHNOLOGY 16.10.2025

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.

Text size:

On April 14, 2025, Nasdaq Staff notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Listing Rule 5550(a)(2). However, Staff has since determined that for the 11 consecutive business days from September 30, 2025 through October 14, 2025, the closing bid price of Lunai Bioworks' common stock was at or above $1.00 per share. As a result, the Company has now regained compliance with the rule and remains eligible for continued listing on The Nasdaq Capital Market.

"This compliance milestone reflects our commitment to strategic execution and shareholder value during a transformative period for Lunai Bioworks," said David Weinstein, Chief Executive Officer. "We remain focused on advancing our AI-powered platform and delivering long-term impact across drug discovery and biodefense."

About Lunai Bioworks

Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.

Media Contact:

David Weinstein
Chief Executive Officer
305-918-1980
[email protected]
http://www.lunaibioworks.com/

SOURCE: Lunai Bioworks Inc.

View the original press release on ACCESS Newswire

T.Wright--AT

Arizona Tribune - Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Featured

Estimating Edge Releases New Article on Time Tracking's Role in Estimating Accuracy

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

Rain Enhancement Technologies Recognized With 2026 "AgTech Climate Innovation of the Year" by AgTech Breakthrough

Aureus Greenway Holdings Inc. and and Powerus Announce $22.3 Million Commercial Contract to Protect Critical Energy Infrastructure in the Middle East